Research at the Clayton Foundation has led to several FDA approved drugs, medical devices and diagnostic assays along with the following pipeline in development by our licensees.
Clinical Pipeline
Lenti-D
Indication: Cerebral ALD
Phase II / III
LentiGlobin BB305
Indication: Beta Thalassemia
Phase III
LentiGlobin BB305
Indication: Sickle Cell Disease
Phase I / II
bb2121 BCMA
Indication: Multiple Myeloma
Breakthrough Designation
OXB-201
Indication: AMD
Phase I Completed
OXB-202
Indication: Corneal Graft
Phase I / II
PEC-Encap VC-01
Indication: T1 and Insulin-requiring T2 Diabetes
Phase I / II
PEC-Direct VC-02
Indication: High-risk T1 Diabetes
Phase I / II
Oral Vimo-001
Indication: Solid Tumors
Phase I
Pre-Clinical Pipeline
RT-200
Indication: Type II Diabetes
Advanced Preclinical
RT-300
Indication: Congestive Heart Failure
Preclinical
RT-400
Indication: Acute decompensated heart failure
Preclinical
GrB-Fc-SD1
Indication: Mesotheliomas & Pancreatic Cancers
Preclinical
Grb-Fc-IT4
Indication: Breast, Lung, Melanoma Cancers
Preclinical
Grb-Fc-4D5
Indication: Breast, GEJ Ca Cancers
Preclinical
Grb-Fc-HMEL
Indication: Melanoma, Breast Cancers
Preclinical
Early Stage Pipeline
JamC mAb
Indication: B Cell Lymphomas
Animal in vivo POC
Olf mAb
Indication: Metastatic breast cancer
Animal in vivo POC
SrpX2 mAb
Indication: TBD
Animal in vivo POC
DHS Fc Domain
Fc domain for antibody half-life extension
Animal POC
GrB platform
Platform technology potent elimination of unwanted cells
Animal POC
SmartKnife
Applications: Chronic Total Occlusions (CTOs), Endometriosis, Brain tumors
Prototype development
Grp78 mAb
Indication: Ovarian cancer
Candidate Selection
Filaggrin-RMR
Indication: Severe Icthyosis Vulgaris
Animal in vivo POC
Fc domains
Platform: Various applications
Research
Stem Cell Safety Switch
Indication: Stem Cell Therapy in CNS (PD…)
Preclinical
E. canis Vaccine
Indication: Ehrlichiosis Canis
Research